Study spells out adverse events that sank Merck's Tredaptive

New data on Merck's ($MRK) withdrawn cholesterol drug Tredaptive, a combination of niacin and an experimental drug laropiprant, shows that one-quarter of patients in a new trial withdrew because of side effects such as itching, rashes and muscle problems. Dozens of patients experienced serious reactions. Report